Papillomavirus Infection
10
4
4
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
40%
4 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Zopa Retreatment and Vector Shedding in Adults With RRP
Impact of an e-Bug Educational Intervention on HPV Vaccine Uptake in Middle School Students
HPV Self-Sampling in Somali Women (Isbaar Project)
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
Acceptability of Human Papillomavirus Self-sampling in Women Living With HIV
HPV Prevalence in Transpersons - a Prospective Study
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine